AHR antagonist 5, a highly potent and orally bioavailable aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1. References: [1]. Alfredo C. Castro, et al. Indole ahr inhibitors and uses thereof. WO2018195397A2.